CR20210624A - Inhibidor de egfr para el tratamiento de cáncer - Google Patents
Inhibidor de egfr para el tratamiento de cáncerInfo
- Publication number
- CR20210624A CR20210624A CR20210624A CR20210624A CR20210624A CR 20210624 A CR20210624 A CR 20210624A CR 20210624 A CR20210624 A CR 20210624A CR 20210624 A CR20210624 A CR 20210624A CR 20210624 A CR20210624 A CR 20210624A
- Authority
- CR
- Costa Rica
- Prior art keywords
- cancer
- treatment
- egfr inhibitor
- ring
- microcytic
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 229940121647 egfr inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- INRNDPUMEATXKG-UHFFFAOYSA-N 6,7-dihydro-5h-pyrrolo[1,2-c]imidazole Chemical group N1=CN2CCCC2=C1 INRNDPUMEATXKG-UHFFFAOYSA-N 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010027540 Microcytosis Diseases 0.000 abstract 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto de fórmula (I) que contiene un anillo tiazol, un anillo indazol y un sistema de anillo 6,7-dihidro-5H-pirrolo [1,2-c]imidazol, a las composiciones farmacéuticas que lo contienen y a su uso médico. Los compuestos se describen como inhibidores alostéricos selectivos de T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S que contienen mutantes de EGFR y, de este modo, son útiles para el tratamiento de cáncer, en particular, cáncer de pulmón no microcítico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19181754 | 2019-06-21 | ||
| PCT/EP2020/067076 WO2020254562A1 (en) | 2019-06-21 | 2020-06-19 | Egfr inhibitor for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210624A true CR20210624A (es) | 2022-02-14 |
Family
ID=67139601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210624A CR20210624A (es) | 2019-06-21 | 2020-06-19 | Inhibidor de egfr para el tratamiento de cáncer |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US12344613B2 (es) |
| EP (4) | EP3986898B1 (es) |
| JP (4) | JP7550799B2 (es) |
| KR (1) | KR102913816B1 (es) |
| CN (4) | CN114008049B (es) |
| AR (4) | AR119210A1 (es) |
| AU (1) | AU2020295703B2 (es) |
| BR (1) | BR112021025445B1 (es) |
| CA (1) | CA3140485A1 (es) |
| CL (1) | CL2021003408A1 (es) |
| CO (1) | CO2021017173A2 (es) |
| CR (1) | CR20210624A (es) |
| DK (1) | DK3986897T3 (es) |
| ES (1) | ES2961187T3 (es) |
| FI (1) | FI3986897T3 (es) |
| HR (1) | HRP20231276T1 (es) |
| HU (1) | HUE063676T2 (es) |
| IL (1) | IL288522B2 (es) |
| LT (1) | LT3986897T (es) |
| MA (1) | MA56508B1 (es) |
| MX (1) | MX2021015464A (es) |
| MY (1) | MY209340A (es) |
| PE (1) | PE20220576A1 (es) |
| PH (1) | PH12021553190A1 (es) |
| PL (1) | PL3986897T3 (es) |
| PT (1) | PT3986897T (es) |
| RS (1) | RS64720B1 (es) |
| SI (1) | SI3986897T1 (es) |
| TW (4) | TW202115053A (es) |
| UA (1) | UA129328C2 (es) |
| WO (4) | WO2020254562A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114008049B (zh) * | 2019-06-21 | 2024-07-05 | 豪夫迈·罗氏有限公司 | 用于癌症治疗的egfr抑制剂 |
| CN113993591A (zh) * | 2019-06-21 | 2022-01-28 | 豪夫迈·罗氏有限公司 | 新egfr抑制剂 |
| IL326879A (en) | 2019-11-11 | 2026-04-01 | Dana Farber Cancer Inst Inc | EGFR allosteric inhibitors and methods of using them |
| CN116600806A (zh) * | 2020-12-01 | 2023-08-15 | 豪夫迈·罗氏有限公司 | 新的吲唑衍生物 |
| JP7840324B2 (ja) | 2020-12-01 | 2026-04-03 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規インダゾール誘導体 |
| JP2024521791A (ja) * | 2021-05-26 | 2024-06-04 | シーフォー セラピューティクス， インコーポレイテッド | 脳又はｃｎｓへの癌転移を治療するためのｅｇｆｒデグレーダー |
| JP2025515833A (ja) * | 2022-05-13 | 2025-05-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規インダゾール誘導体 |
| JP2025516543A (ja) * | 2022-05-13 | 2025-05-30 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のためのアロステリックおよびオルソステリックｅｇｆｒ阻害剤の組み合わせ |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0508715D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
| CN101273033A (zh) * | 2005-09-20 | 2008-09-24 | 阿斯利康(瑞典)有限公司 | 作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-（1h-吲哚-5-基-氨基）-喹唑啉化合物 |
| ES2408932T3 (es) | 2008-06-25 | 2013-06-24 | Merck Sharp & Dohme Corp. | Síntesis y uso de agentes antibacterianos heterocíclicos |
| US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| CN105209456B (zh) | 2013-03-06 | 2018-05-08 | 阿斯利康(瑞典)有限公司 | 表皮生长因子受体的活化突变形式的喹唑啉抑制剂 |
| WO2015095807A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of egfr and erk inhibitors |
| WO2016000615A1 (en) * | 2014-07-02 | 2016-01-07 | Sunshine Lake Pharma Co., Ltd. | Heteroaryl compounds and pharmaceutical applications thereof |
| WO2016077375A1 (en) * | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Bromodomain inhibitors and uses thereof |
| AU2016262572B2 (en) | 2015-05-14 | 2020-04-30 | The Wistar Institute Of Anatomy And Biology | EBNA1 inhibitors and methods using same |
| CA2987914C (en) | 2015-06-30 | 2022-09-13 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| TW201834651A (zh) * | 2016-12-22 | 2018-10-01 | 瑞士商赫孚孟拉羅股份公司 | 化合物 |
| WO2018220149A1 (en) * | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Compounds |
| JP7191045B2 (ja) | 2017-06-02 | 2022-12-16 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 化合物 |
| WO2019046668A1 (en) * | 2017-08-31 | 2019-03-07 | Kezar Life Sciences | AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN |
| SG11202011818YA (en) | 2018-06-29 | 2020-12-30 | Hoffmann La Roche | Compounds |
| CN113993591A (zh) | 2019-06-21 | 2022-01-28 | 豪夫迈·罗氏有限公司 | 新egfr抑制剂 |
| JP7561777B2 (ja) * | 2019-06-21 | 2024-10-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規ｅｇｆｒ阻害剤 |
| CN114008049B (zh) | 2019-06-21 | 2024-07-05 | 豪夫迈·罗氏有限公司 | 用于癌症治疗的egfr抑制剂 |
| AR120800A1 (es) | 2019-12-20 | 2022-03-16 | Hoffmann La Roche | Derivados de 6,7-dihidro-5h-pirrolo[1,2-c]imidazol como inhibidores de egfr |
| AR120799A1 (es) | 2019-12-20 | 2022-03-16 | Hoffmann La Roche | 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr |
| JP7840324B2 (ja) | 2020-12-01 | 2026-04-03 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規インダゾール誘導体 |
| PE20240099A1 (es) | 2020-12-01 | 2024-01-18 | Hoffmann La Roche | Nuevos derivados de indazol acetileno |
| CN116600806A (zh) | 2020-12-01 | 2023-08-15 | 豪夫迈·罗氏有限公司 | 新的吲唑衍生物 |
| JP2025516543A (ja) | 2022-05-13 | 2025-05-30 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のためのアロステリックおよびオルソステリックｅｇｆｒ阻害剤の組み合わせ |
| JP2025515833A (ja) | 2022-05-13 | 2025-05-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規インダゾール誘導体 |
-
2020
- 2020-06-19 CN CN202080044300.3A patent/CN114008049B/zh active Active
- 2020-06-19 PH PH1/2021/553190A patent/PH12021553190A1/en unknown
- 2020-06-19 JP JP2021576020A patent/JP7550799B2/ja active Active
- 2020-06-19 UA UAA202107497A patent/UA129328C2/uk unknown
- 2020-06-19 WO PCT/EP2020/067076 patent/WO2020254562A1/en not_active Ceased
- 2020-06-19 EP EP20734872.3A patent/EP3986898B1/en active Active
- 2020-06-19 MA MA56508A patent/MA56508B1/fr unknown
- 2020-06-19 US US17/620,239 patent/US12344613B2/en active Active
- 2020-06-19 AR ARP200101749A patent/AR119210A1/es not_active Application Discontinuation
- 2020-06-19 CA CA3140485A patent/CA3140485A1/en active Pending
- 2020-06-19 WO PCT/EP2020/067086 patent/WO2020254568A1/en not_active Ceased
- 2020-06-19 TW TW109120782A patent/TW202115053A/zh unknown
- 2020-06-19 TW TW109120781A patent/TWI869416B/zh active
- 2020-06-19 PL PL20734871.5T patent/PL3986897T3/pl unknown
- 2020-06-19 TW TW109120783A patent/TW202115072A/zh unknown
- 2020-06-19 LT LTEPPCT/EP2020/067076T patent/LT3986897T/lt unknown
- 2020-06-19 BR BR112021025445-5A patent/BR112021025445B1/pt active IP Right Grant
- 2020-06-19 CR CR20210624A patent/CR20210624A/es unknown
- 2020-06-19 FI FIEP20734871.5T patent/FI3986897T3/fi active
- 2020-06-19 EP EP20734871.5A patent/EP3986897B1/en active Active
- 2020-06-19 CN CN202080043708.9A patent/CN113966335B/zh active Active
- 2020-06-19 AR ARP200101747A patent/AR119208A1/es not_active Application Discontinuation
- 2020-06-19 AR ARP200101748A patent/AR119209A1/es not_active Application Discontinuation
- 2020-06-19 CN CN202080045269.5A patent/CN113993873B/zh active Active
- 2020-06-19 US US17/620,240 patent/US20220315593A1/en active Pending
- 2020-06-19 HU HUE20734871A patent/HUE063676T2/hu unknown
- 2020-06-19 HR HRP20231276TT patent/HRP20231276T1/hr unknown
- 2020-06-19 JP JP2021576031A patent/JP7550800B2/ja active Active
- 2020-06-19 TW TW109120821A patent/TW202115074A/zh unknown
- 2020-06-19 AU AU2020295703A patent/AU2020295703B2/en active Active
- 2020-06-19 PE PE2021002089A patent/PE20220576A1/es unknown
- 2020-06-19 CN CN202080044011.3A patent/CN113993872B/zh active Active
- 2020-06-19 EP EP20734348.4A patent/EP3986896B1/en active Active
- 2020-06-19 MY MYPI2021007566A patent/MY209340A/en unknown
- 2020-06-19 WO PCT/EP2020/067093 patent/WO2020254572A1/en not_active Ceased
- 2020-06-19 EP EP20734160.3A patent/EP3986895B1/en active Active
- 2020-06-19 JP JP2021576032A patent/JP7530391B2/ja active Active
- 2020-06-19 SI SI202030292T patent/SI3986897T1/sl unknown
- 2020-06-19 IL IL288522A patent/IL288522B2/en unknown
- 2020-06-19 MX MX2021015464A patent/MX2021015464A/es unknown
- 2020-06-19 JP JP2021575205A patent/JP7550798B2/ja active Active
- 2020-06-19 ES ES20734871T patent/ES2961187T3/es active Active
- 2020-06-19 AR ARP200101745A patent/AR119206A1/es unknown
- 2020-06-19 DK DK20734871.5T patent/DK3986897T3/da active
- 2020-06-19 PT PT207348715T patent/PT3986897T/pt unknown
- 2020-06-19 RS RS20230942A patent/RS64720B1/sr unknown
- 2020-06-19 KR KR1020217041612A patent/KR102913816B1/ko active Active
- 2020-06-19 WO PCT/EP2020/067082 patent/WO2020254565A1/en not_active Ceased
- 2020-06-19 US US17/620,242 patent/US12479849B2/en active Active
-
2021
- 2021-12-15 CO CONC2021/0017173A patent/CO2021017173A2/es unknown
- 2021-12-20 CL CL2021003408A patent/CL2021003408A1/es unknown
- 2021-12-21 US US17/558,053 patent/US20220135571A1/en not_active Abandoned
-
2025
- 2025-05-28 US US19/221,423 patent/US20250289824A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021017173A2 (es) | Inhibidor de egfr para el tratamiento de cáncer | |
| AR119207A1 (es) | DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR | |
| CO2022001357A2 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| CO2021007230A2 (es) | Inhibidores de cinasa 7 dependiente de ciclina (cdk7) | |
| CL2019003669A1 (es) | Inhibidores de quinasa alk2 que contienen imidazol. | |
| PH12021550604A1 (en) | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors | |
| GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| CR20200441A (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b | |
| AR041184A1 (es) | Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso | |
| MXPA04002042A (es) | Compuestos de bencimidazol sustituidos y su uso para el tratamiento del cancer. | |
| MX379057B (es) | Compuestos de benzoxaborol y uso de los mismos. | |
| CR20240533A (es) | Macrociclos de indazol y su uso | |
| EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта | |
| BR112023005443A2 (pt) | Derivado de y-carbolina fundido substituído heterocíclico, método de preparação do mesmo, intermediário do mesmo e uso do mesmo | |
| CL2023002632A1 (es) | Derivados de 3h,4h-tieno [2,3-d]pirimidin-4-ona como inhibidores de trpa1 | |
| MX2021009426A (es) | Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer. | |
| CL2021001509A1 (es) | Derivados de xantina sustituida | |
| PY1987737A (es) | Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| PY2061937A (es) | 2- derivados de azaespiro[3.4]octano como agonistas de m4 | |
| CO2023017975A2 (es) | Inhibidores de alk2 quinasa que contienen imidazol | |
| AR131717A1 (es) | Compuestos de imida biciclica como inhibidores de trpa1 | |
| AR133217A1 (es) | Inhibidores de trpa1 bicíclicos y monocíclicos | |
| UY39990A (es) | Nuevos inhibidores de microtúbulos, composiciones farmacéuticas que los contienen, métodos para su fabricación y uso como agentes antitumorales | |
| EA202090644A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-a]ПИРАЗИНА КАК ИНГИБИТОРЫ PI3K |